Irritable bowel syndrome cost-effectiveness of therapy: Difference between revisions
(Created page with "__NOTOC__ {{Template:Irritable bowel syndrome}} {{CMG}} ==Overview== ==Cost-effectiveness of therapy== The aggregate cost of irritable bowel syndrome in the United States has...") |
No edit summary |
||
| Line 33: | Line 33: | ||
| id = PMID 17593069 | | id = PMID 17593069 | ||
| }}</ref>A study of workers with IBS found that they reported a 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.<ref name="PARE_2006">{{cite journal |author=Paré P, Gray J, Lam S, ''et al'' |title=Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study |journal=Clinical therapeutics |volume=28|issue=10 |pages=1726–35; discussion 1710–1 |year=2006 |pmid=17157129 |doi=10.1016/j.clinthera.2006.10.010}}</ref> A study of employer-related health costs from a Fortune 100 company conducted with data from the 1990's found IBS patients incurred US $4527 in claims costs vs. $3276 for controls.<ref name="LEONG_2003">{{cite journal |author=Leong SA, Barghout V, Birnbaum HG, ''et al''|title=The economic consequences of irritable bowel syndrome: a US employer perspective |journal=Arch. Intern. Med. |volume=163|issue=8 |pages=929–35 |year=2003 |pmid=12719202 |doi=10.1001/archinte.163.8.929}}</ref> A study on Medicaid costs conducted in 2003 by the University of Georgia's College of Pharmacy and [[Novartis]] found IBS was associated in an increase of $962 in Medicaid costs in California, and $2191 in North Carolina. IBS patients had higher costs for physician visits, outpatients visits, and prescription drugs. The study suggested the costs associated with IBS were comparable to those found in asthma patients.<ref name="MARTIN_2003">{{cite journal |author=Martin B, Ganguly R, Pannicker S, Feride F;Barghout V|title=Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome |journal=Curr Med Res Opin|volume=19 |issue=8 |pages=771-780 |year=2003|pmid=12719202 |url=http://www.medscape.com/viewarticle/465472}}</ref> | | }}</ref>A study of workers with IBS found that they reported a 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.<ref name="PARE_2006">{{cite journal |author=Paré P, Gray J, Lam S, ''et al'' |title=Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study |journal=Clinical therapeutics |volume=28|issue=10 |pages=1726–35; discussion 1710–1 |year=2006 |pmid=17157129 |doi=10.1016/j.clinthera.2006.10.010}}</ref> A study of employer-related health costs from a Fortune 100 company conducted with data from the 1990's found IBS patients incurred US $4527 in claims costs vs. $3276 for controls.<ref name="LEONG_2003">{{cite journal |author=Leong SA, Barghout V, Birnbaum HG, ''et al''|title=The economic consequences of irritable bowel syndrome: a US employer perspective |journal=Arch. Intern. Med. |volume=163|issue=8 |pages=929–35 |year=2003 |pmid=12719202 |doi=10.1001/archinte.163.8.929}}</ref> A study on Medicaid costs conducted in 2003 by the University of Georgia's College of Pharmacy and [[Novartis]] found IBS was associated in an increase of $962 in Medicaid costs in California, and $2191 in North Carolina. IBS patients had higher costs for physician visits, outpatients visits, and prescription drugs. The study suggested the costs associated with IBS were comparable to those found in asthma patients.<ref name="MARTIN_2003">{{cite journal |author=Martin B, Ganguly R, Pannicker S, Feride F;Barghout V|title=Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome |journal=Curr Med Res Opin|volume=19 |issue=8 |pages=771-780 |year=2003|pmid=12719202 |url=http://www.medscape.com/viewarticle/465472}}</ref> | ||
==Research spending on IBS== | |||
{{Further|[[NIH funding of IBS Research]]}} | |||
The [[National Institutes of Health]] provides a searchable database for grant awards since 1974 on its [[CRISP]] database, and provides dollar amounts for recent awards on its [http://grants.nih.gov/grants/award/trends/AggregateData.cfm Intramural Grant Award Page]. | |||
In 2006, the NIH awarded approximately 56 grants related to IBS, totalling approximately $18,787,710. | |||
==References== | ==References== | ||
Revision as of 17:55, 22 August 2012
|
Irritable bowel syndrome Microchapters |
|
Differentiating Irritable bowel syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Irritable bowel syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Irritable bowel syndrome cost-effectiveness of therapy |
|
FDA on Irritable bowel syndrome cost-effectiveness of therapy |
|
CDC on Irritable bowel syndrome cost-effectiveness of therapy |
|
Irritable bowel syndrome cost-effectiveness of therapy in the news |
|
Blogs on Irritable bowel syndrome cost-effectiveness of therapy |
|
Risk calculators and risk factors for Irritable bowel syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cost-effectiveness of therapy
The aggregate cost of irritable bowel syndrome in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.[1] A study by a managed care company comparing medical costs of IBS patients to non-IBS controls identified a 49% annual increase in medical costs associated with a diagnosis of IBS.[2] A 2007 study from a managed care oganization found that IBS patients incurred average annual direct costs of $5,049 and $406 in out-of-pocket expenses.[3]A study of workers with IBS found that they reported a 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.[4] A study of employer-related health costs from a Fortune 100 company conducted with data from the 1990's found IBS patients incurred US $4527 in claims costs vs. $3276 for controls.[5] A study on Medicaid costs conducted in 2003 by the University of Georgia's College of Pharmacy and Novartis found IBS was associated in an increase of $962 in Medicaid costs in California, and $2191 in North Carolina. IBS patients had higher costs for physician visits, outpatients visits, and prescription drugs. The study suggested the costs associated with IBS were comparable to those found in asthma patients.[6]
Research spending on IBS
The National Institutes of Health provides a searchable database for grant awards since 1974 on its CRISP database, and provides dollar amounts for recent awards on its Intramural Grant Award Page. In 2006, the NIH awarded approximately 56 grants related to IBS, totalling approximately $18,787,710.
References
- ↑ Hulisz D. (2004). "The burden of illness of irritable bowel syndrome: current challenges and hope for the future". J Manag Care Pharm. 10 (4): 299–309. PMID 15298528.
- ↑ Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. (2001). "Costs of care for irritable bowel syndrome patients in a health maintenance organization". Am J Gastroenterol. 96 (11): 3122–9. PMID 11721759.
- ↑ "Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain". Aliment Pharmacol Ther. 26 (2): 237–48. 2007. PMID 17593069. Text " author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. " ignored (help)
- ↑ Paré P, Gray J, Lam S; et al. (2006). "Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study". Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
- ↑ Leong SA, Barghout V, Birnbaum HG; et al. (2003). "The economic consequences of irritable bowel syndrome: a US employer perspective". Arch. Intern. Med. 163 (8): 929–35. doi:10.1001/archinte.163.8.929. PMID 12719202.
- ↑ Martin B, Ganguly R, Pannicker S, Feride F;Barghout V (2003). "Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome". Curr Med Res Opin. 19 (8): 771–780. PMID 12719202.